210 related articles for article (PubMed ID: 37367629)
21. Risk factors and clinical significance of bacteremia caused by Pseudomonas aeruginosa resistant only to carbapenems.
Lee CH; Su TY; Ye JJ; Hsu PC; Kuo AJ; Chia JH; Lee MH
J Microbiol Immunol Infect; 2017 Oct; 50(5):677-683. PubMed ID: 26188977
[TBL] [Abstract][Full Text] [Related]
22. Effect of Combination Antibiotic Empirical Therapy on Mortality in Neutropenic Cancer Patients with
Albasanz-Puig A; Durà-Miralles X; Laporte-Amargós J; Mussetti A; Ruiz-Camps I; Puerta-Alcalde P; Abdala E; Oltolini C; Akova M; Montejo JM; Mikulska M; Martín-Dávila P; Herrera F; Gasch O; Drgona L; Morales HMP; Brunel AS; García E; Isler B; Kern WV; Retamar-Gentil P; Aguado JM; Montero M; Kanj SS; Sipahi OR; Calik S; Márquez-Gómez I; Marin JI; Gomes MZR; Hemmati P; Araos R; Peghin M; Del Pozo JL; Yáñez L; Tilley R; Manzur A; Novo A; Pallarès N; Bergas A; Carratalà J; Gudiol C; On Behalf Of The Ironic Study Group
Microorganisms; 2022 Mar; 10(4):. PubMed ID: 35456784
[TBL] [Abstract][Full Text] [Related]
23. Rates, predictors and mortality of community-onset bloodstream infections due to Pseudomonas aeruginosa: systematic review and meta-analysis.
Rojas A; Palacios-Baena ZR; López-Cortés LE; Rodríguez-Baño J
Clin Microbiol Infect; 2019 Aug; 25(8):964-970. PubMed ID: 30995530
[TBL] [Abstract][Full Text] [Related]
24. Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Kleinhendler E; Cohen MJ; Moses AE; Paltiel O; Strahilevitz J; Cahan A
Int J Antimicrob Agents; 2018 Jan; 51(1):71-76. PubMed ID: 28705670
[TBL] [Abstract][Full Text] [Related]
25. Fluoroquinolone Prophylaxis Selects for Meropenem-nonsusceptible Pseudomonas aeruginosa in Patients With Hematologic Malignancies and Hematopoietic Cell Transplant Recipients.
Hakki M; Humphries RM; Hemarajata P; Tallman GB; Shields RK; Mettus RT; Doi Y; Lewis JS
Clin Infect Dis; 2019 May; 68(12):2045-2052. PubMed ID: 30256922
[TBL] [Abstract][Full Text] [Related]
26. Pseudomonas aeruginosa bacteremia: resistance to antibiotics, risk factors, and patient mortality.
Vitkauskienė A; Skrodenienė E; Dambrauskienė A; Macas A; Sakalauskas R
Medicina (Kaunas); 2010; 46(7):490-5. PubMed ID: 20966623
[TBL] [Abstract][Full Text] [Related]
27. Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Babich T; Naucler P; Valik JK; Giske CG; Benito N; Cardona R; Rivera A; Pulcini C; Abdel Fattah M; Haquin J; Macgowan A; Grier S; Gibbs J; Chazan B; Yanovskay A; Ben Ami R; Landes M; Nesher L; Zaidman-Shimshovitz A; McCarthy K; Paterson DL; Tacconelli E; Buhl M; Mauer S; Rodriguez-Bano J; Morales I; Oliver A; Ruiz De Gopegui E; Cano A; Machuca I; Gozalo-Marguello M; Martinez Martinez L; Gonzalez-Barbera EM; Alfaro IG; Salavert M; Beovic B; Saje A; Mueller-Premru M; Pagani L; Vitrat V; Kofteridis D; Zacharioudaki M; Maraki S; Weissman Y; Paul M; Dickstein Y; Leibovici L; Yahav D
Clin Infect Dis; 2020 May; 70(11):2270-2280. PubMed ID: 31323088
[TBL] [Abstract][Full Text] [Related]
28. Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey.
Trecarichi EM; Giuliano G; Cattaneo C; Ballanti S; Criscuolo M; Candoni A; Marchesi F; Laurino M; Dargenio M; Fanci R; Cefalo M; Delia M; Spolzino A; Maracci L; Bonuomo V; Busca A; Principe MID; Daffini R; Simonetti E; Dragonetti G; Zannier ME; Pagano L; Tumbarello M;
Int J Antimicrob Agents; 2023 Jun; 61(6):106806. PubMed ID: 37030470
[TBL] [Abstract][Full Text] [Related]
29. Pseudomonas aeruginosa bacteraemia in patients with hematologic malignancies: risk factors, treatment and outcome.
Tofas P; Samarkos M; Piperaki ET; Kosmidis C; Triantafyllopoulou ID; Kotsopoulou M; Pantazatou A; Perlorentzou S; Poulli A; Vagia M; Daikos GL
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):335-341. PubMed ID: 28529091
[TBL] [Abstract][Full Text] [Related]
30. Bloodstream infections in patients with solid tumors: epidemiology, antibiotic therapy, and outcomes in 528 episodes in a single cancer center.
Marín M; Gudiol C; Garcia-Vidal C; Ardanuy C; Carratalà J
Medicine (Baltimore); 2014 May; 93(3):143-149. PubMed ID: 24797169
[TBL] [Abstract][Full Text] [Related]
31. Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence.
Recio R; Mancheño M; Viedma E; Villa J; Orellana MÁ; Lora-Tamayo J; Chaves F
Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31767719
[TBL] [Abstract][Full Text] [Related]
32.
Herrera S; Morata L; Sempere A; Verdejo M; Del Rio A; Martínez JA; Cuervo G; Hernández-Meneses M; Chumbita M; Pitart C; Puerta P; Monzó P; Lopera C; Aiello F; Mendoza S; Garcia-Vidal C; Soriano A; Bodro M
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830291
[TBL] [Abstract][Full Text] [Related]
33. Influence of multidrug resistance and appropriate empirical therapy on the 30-day mortality rate of Pseudomonas aeruginosa bacteremia.
Morata L; Cobos-Trigueros N; Martínez JA; Soriano A; Almela M; Marco F; Sterzik H; Núñez R; Hernández C; Mensa J
Antimicrob Agents Chemother; 2012 Sep; 56(9):4833-7. PubMed ID: 22751533
[TBL] [Abstract][Full Text] [Related]
34.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
35. Impact of the Inclusion of an Aminoglycoside to the Initial Empirical Antibiotic Therapy for Gram-Negative Bloodstream Infections in Hematological Neutropenic Patients: a Propensity-Matched Cohort Study (AMINOLACTAM Study).
Albasanz-Puig A; Gudiol C; Puerta-Alcalde P; Ayaz CM; Machado M; Herrera F; Martín-Dávila P; Laporte-Amargós J; Cardozo C; Akova M; Álvarez-Uría A; Torres D; Fortún J; García-Vidal C; Muñoz P; Bergas A; Pomares H; Mercadal S; Durà-Miralles X; García-Lerma E; Pallarès N; Carratalà J
Antimicrob Agents Chemother; 2021 Jul; 65(8):e0004521. PubMed ID: 33972253
[TBL] [Abstract][Full Text] [Related]
36. P. aeruginosa bloodstream infections among hematological patients: an old or new question?
Cattaneo C; Antoniazzi F; Casari S; Ravizzola G; Gelmi M; Pagani C; D'Adda M; Morello E; Re A; Borlenghi E; Manca N; Rossi G
Ann Hematol; 2012 Aug; 91(8):1299-304. PubMed ID: 22349723
[TBL] [Abstract][Full Text] [Related]
37. Determinants of empirical antipseudomonal antibiotic prescription for adults with pneumonia in the emergency department.
Angrill N; Gallego M; Font J; Vallés J; Morón A; Monsó E; Rello J
BMC Pulm Med; 2020 Apr; 20(1):83. PubMed ID: 32245452
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of studies on extended versus standard infusion of beta-lactam antibiotics.
Chen M; Buurma V; Shah M; Fahim G
Am J Health Syst Pharm; 2019 Sep; 76(18):1383-1394. PubMed ID: 31505562
[TBL] [Abstract][Full Text] [Related]
39. Bloodstream infections in neutropenic patients with haematological malignancies.
Carvalho AS; Lagana D; Catford J; Shaw D; Bak N
Infect Dis Health; 2020 Feb; 25(1):22-29. PubMed ID: 31586572
[TBL] [Abstract][Full Text] [Related]
40. [Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Dambrauskiene A; Adukauskiene D; Jeroch J; Vitkauskiene A
Medicina (Kaunas); 2009; 45(1):1-7. PubMed ID: 19223699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
